News Feed

By Lorraine L. Janeczko

NEW YORK (Reuters Health) - Topical ozenoxacin offers a novel, effective and well-tolerated treatment option for impetigo in patients 2 months of age and older, industry-funded research suggest.

By Lisa Rapaport

(Reuters Health) - More than one-third of American adults take medications that have the potential to cause depression, a U.S. study suggests.

By Marilynn Larkin

NEW YORK (Reuters Health) - Patients with hidradenitis suppurativa (HS), a skin disorder characterized by painful nodules and abscesses, may be at increased risk for Crohn's disease (CD), and those with GI symptoms should be seen by a gastroenterologist, researchers in New York say.

By Marilynn Larkin

NEW YORK (Reuters Health) - New criteria for staging melanoma, from the American Joint Committee on Cancer (AJCC), will likely have a positive effect on patients, but concordance and reproducibility "remain low," researchers say.

By Will Boggs MD

NEW YORK (Reuters Health) - Long-term hydrochlorothiazide use appears to be associated with an increased risk of malignant melanoma, researchers from Denmark report.

By Marilynn Larkin

NEW YORK (Reuters Health) - The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests.

By Lisa Rapaport

(Reuters Health) - Children with eczema whose bath water contains added moisturizers may get no more relief from the itchy skin condition than they would without the extra bath products, a study suggests.

By Ronnie Cohen

(Reuters Health) - Hair products used primarily by black women and children contain a host of hazardous chemicals, a new study shows.

By David Douglas

NEW YORK (Reuters Health) - Compared with tumors on the cutaneous lip, cutaneous squamous cell carcinomas (cSCC) on the vermilion lip appears to carry a greater risk of metastasis, researchers have found.

By Marilynn Larkin

NEW YORK (Reuters Health) - Patients with cutaneous lupus erythematosus (CLE) should be monitored closely for other autoimmune conditions, researchers suggest.